Euchrestaflavanone BCAS# 87402-91-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 87402-91-3 | SDF | Download SDF |
PubChem ID | 14542254 | Appearance | Powder |
Formula | C25H28O6 | M.Wt | 424.49 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (2S)-2-[2,4-dihydroxy-5-(3-methylbut-2-enyl)phenyl]-5,7-dihydroxy-8-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one | ||
SMILES | CC(=CCC1=C(C=C(C(=C1)C2CC(=O)C3=C(O2)C(=C(C=C3O)O)CC=C(C)C)O)O)C | ||
Standard InChIKey | IPNPAENNCXAVSJ-QHCPKHFHSA-N | ||
Standard InChI | InChI=1S/C25H28O6/c1-13(2)5-7-15-9-17(20(28)10-18(15)26)23-12-22(30)24-21(29)11-19(27)16(25(24)31-23)8-6-14(3)4/h5-6,9-11,23,26-29H,7-8,12H2,1-4H3/t23-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Euchrestaflavanone B may function by inhibiting oncogenic disease, at least in part, through the inhibition of protein kinase CKII activity. 2. Euchrestaflavanone B shows antibacterial activity against Gram positive bacteria, Staphylococcus aureus, Bacillus subtilis and Bacillus cereus. |
Targets | PARP | Antifection |
Euchrestaflavanone B Dilution Calculator
Euchrestaflavanone B Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.3558 mL | 11.7788 mL | 23.5577 mL | 47.1154 mL | 58.8942 mL |
5 mM | 0.4712 mL | 2.3558 mL | 4.7115 mL | 9.4231 mL | 11.7788 mL |
10 mM | 0.2356 mL | 1.1779 mL | 2.3558 mL | 4.7115 mL | 5.8894 mL |
50 mM | 0.0471 mL | 0.2356 mL | 0.4712 mL | 0.9423 mL | 1.1779 mL |
100 mM | 0.0236 mL | 0.1178 mL | 0.2356 mL | 0.4712 mL | 0.5889 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Denudatin B
Catalog No.:BCN4558
CAS No.:87402-88-8
- 2,3-Dihydroamentoflavone 7,4'-dimethyl ether
Catalog No.:BCN1320
CAS No.:873999-88-3
- Neotriangularine
Catalog No.:BCN2052
CAS No.:87392-67-4
- 3,4,5'-Trimethoxy-3',4'-methylenedioxy-7,9':7',9-diepoxylignan
Catalog No.:BCN7238
CAS No.:873867-94-8
- Fidaxomicin
Catalog No.:BCC4660
CAS No.:873857-62-6
- BMS-599626 Hydrochloride
Catalog No.:BCC1426
CAS No.:873837-23-1
- TATU
Catalog No.:BCC2822
CAS No.:873798-09-5
- PLX647
Catalog No.:BCC6370
CAS No.:873786-09-5
- Omecamtiv mecarbil
Catalog No.:BCC3710
CAS No.:873697-71-3
- Demethylcarolignan E
Catalog No.:BCN7018
CAS No.:873694-46-3
- GDC-0152
Catalog No.:BCC2252
CAS No.:873652-48-3
- Lupeolic acid
Catalog No.:BCN6520
CAS No.:87355-32-6
- RO4987655
Catalog No.:BCC5135
CAS No.:874101-00-5
- Daphnilongeranin A
Catalog No.:BCN4418
CAS No.:874201-05-5
- Liriopesides B
Catalog No.:BCN2811
CAS No.:87425-34-1
- Millewanin G
Catalog No.:BCN6461
CAS No.:874303-33-0
- Millewanin H
Catalog No.:BCN6465
CAS No.:874303-34-1
- Glepidotin B
Catalog No.:BCN4844
CAS No.:87440-56-0
- 6-Dehydroxy-8-hydroxygaleopsinolone
Catalog No.:BCN7402
CAS No.:87440-66-2
- Viteralone
Catalog No.:BCN4419
CAS No.:87440-75-3
- 11(13)-Dehydroivaxillin
Catalog No.:BCN4420
CAS No.:87441-73-4
- SEN 12333
Catalog No.:BCC6182
CAS No.:874450-44-9
- Schizanrin L
Catalog No.:BCN3620
CAS No.:874472-16-9
- (25RS)-Ruscogenin
Catalog No.:BCN7805
CAS No.:874485-32-2
Inhibition of protein kinase CKII activity by euchrestaflavanone B purified from Cudrania tricuspidata.[Pubmed:16408697]
Oncol Res. 2005;15(6):327-32.
The CKII (EC 2.7.1.37) inhibitory compound was purified from the root barks of Cudrania tricuspidata and identified as (2S)-2-[2,4-dihydroxy-5-(3-methyl-but-2-enyl)-phenyl]-5,7-dihyroxy-6-(3-methyl-bu t-2-enyl)chroman-4-one (Euchrestaflavanone B). Euchrestaflavanone B was shown to inhibit the phosphotransferase activity of CKII with IC50 of about 78 microM. Steady-state studies revealed that Euchrestaflavanone B acted as a competitive inhibitor with respect to the substrate ATP. A value of 16.4 microM was obtained for the apparent Ki. Concentration of 0.8 microM Euchrestaflavanone B caused 50% growth inhibition of human cancer cells U937 and HeLa. Euchrestaflavanone B-induced cell death was characterized with the cleavage of poly(ADP-ribose) polymerase and procaspase-3, indicating that the inhibitor triggered apoptosis. Because protein kinase CKII is involved in cell proliferation and oncogenesis, these results suggest that Euchrestaflavanone B may function by inhibiting oncogenic disease, at least in part, through the inhibition of CKII activity.